LYMPHOMA & MYELOMA CONNECT is an international group of experts in the field of hematological malignancies and is an initiative of COR2ED. The group discusses the latest scientific and clinical insights, identifies educational needs, and develops educational programmes to support healthcare professionals globally to provide the best possible care to their patients.
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
The third episode in the series, Dr. María Victoria Mateos and Dr. Alexander Lesokhin discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.
Dr Claudio Cerchione summarises highlights from SOHO, SOHO Italy and IMW 2021